Quantcast

Latest Retina Stories

2014-10-27 12:26:23

Desire for Greater Efficacy and Improved Convenience Drive Perceived Value of Emerging Therapies for Wet Form of the Disease, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 27, 2014 /PRNewswire/ -- Decision Resources Group finds that retinal specialists in the EU5 (France, Germany, Italy, Spain, and the United Kingdom) report patient share for Bayer's Eylea, the most recently launched anti-vascular endothelial growth factor (VEGF) agent for the treatment of wet...

2014-10-22 08:33:26

Study Finds Visual Function Improves in Majority of Patients Implanted with the CE Marked Alpha IMS Subretinal Microchip CHICAGO, Oct. 22, 2014 /PRNewswire/ -- Retina Implant AG, the leading developer of subretinal implants for patients blinded by retinitis pigmentosa (RP), today announced that Dr. Helmut Sachs, senior consultant and head of the Department of Ophthalmology, Clinic Dresden-Friedrichstadt, Germany presented patient outcomes at one year post-implantation of the CE...

2014-10-21 16:28:12

The American Optometric Association reminds patients that yearly, comprehensive eye exams remain a critical pathway to eye and vision health ST. LOUIS, Oct. 21, 2014 /PRNewswire-USNewswire/ -- Early symptoms of diabetic eye and vision disorders are often subtle or unnoticed, but new technology, coupled with yearly, comprehensive eye exams, are improving patient outcomes and leading to earlier detection of eye diseases, including those associated with diabetes, which now affects 29 million...

2014-10-17 08:25:21

Fourteen Physicians, Eight New to the IRIDEX Podium, will Share their Experiences using MicroPulse® Laser Therapy for Retina and Glaucoma MOUNTAIN VIEW, Calif., Oct. 17, 2014 /PRNewswire/ -- IRIDEX Corporation (Nasdaq:IRIX) announced today its Speakers' Forum program at the annual meeting of the American Academy of Ophthalmology to be held on October 18 - 21 at McCormick Place in Chicago. The Forum consists of a comprehensive 3-day schedule of activities at the IRIDEX booth featuring 13...

2014-10-16 23:03:41

Licensing Agreement Signed For Canadian Market Expected Revenue In Excess Of $30MM USD (PRWEB) October 16, 2014 The Eye Machine, LLC today announced the signing of an agreement providing Eye Machine Canada the exclusive rights to market the company’s non-invasive treatment for macular degeneration. This agreement is expected to provide The Eye Machine a cash flow in excess of $30 million USD over the first ten years following FDA trial completion and approval from both licensing and...

2014-10-14 08:32:02

- AIMing to establish a new treatment for ophthalmologic diseases - TOKYO, Oct. 14, 2014 /PRNewswire/ -- Astellas Pharma Inc. (Tokyo: 4503, President & CEO: Yoshihiko Hatanaka, "Astellas") announced today a research collaboration with an investigator at Harvard Medical School ("Harvard"), located in Boston, Massachusetts, USA, focused on discovering the pathologic mechanism for retinitis pigmentosa and identification of new therapeutic targets. Astellas and Harvard will work with...

2014-10-14 08:30:56

MOUNTAIN VIEW, Calif., Oct. 14, 2014 /PRNewswire/ -- IRIDEX Corporation (Nasdaq:IRIX) announced today that it will introduce its new family of patented Adjustable & Intuitive Extended Reach (A&I XR) laser probes at the annual meeting of the American Academy of Ophthalmology to be held October 18 - 21 at McCormick Place in Chicago. The A&I XR laser probes are used for laser photocoagulation during vitreoretinal procedures. These new devices offer unprecedented uniformity...

2014-10-13 08:27:07

SARATOGA, Calif., Oct. 13, 2014 /PRNewswire/ -- VisionCare Ophthalmic Technologies, Inc. ("VisionCare"), a developer of advanced visual prosthetic devices for the treatment of age-related macular degeneration (AMD), today announced the U.S. Food and Drug Administration approved the Implantable Miniature Telescope (by Dr. Isaac Lipshitz) for use in patients living with bilateral end-stage age-related macular degeneration who are age 65 or older. The telescope implant is the only FDA...

2014-10-09 23:00:29

Findings help product development at Diopsys, Inc. Pine Brook, NJ (PRWEB) October 10, 2014 Research scientists from the University of Alabama, Birmingham (UAB), Gladstone Institutes and University of California, San Francisco published findings in the Journal of Experimental Medicine stating there is a direct correlation with functional cell loss in the retina and signs of dementia in people with a genetic risk for frontotemporal dementia (FTD). The study shows that changes in the retina...

2014-10-08 23:00:26

New study shows that the Diopsys NOVA-ERG acts as window to the brain Pine Brook, NJ (PRWEB) October 09, 2014 Research scientists from the University of Alabama, Birmingham (UAB), Gladstone Institutes and University of California, San Francisco published findings in the Journal of Experimental Medicine stating there is a direct correlation with functional cell loss in the retina and signs of dementia in people with a genetic risk for frontotemporal dementia (FTD). The study shows that...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related